Skip to content

Assessing the efficacy of exercising with the RESPeRATE device to lower blood pressure in diabetic hypertensives

Assessing the efficacy of exercising with the RESPeRATE device to lower blood pressure in diabetic hypertensives: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN00985733
Enrollment
70
Registered
2007-07-10
Start date
2004-09-01
Completion date
Unknown
Last updated
2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, hypertension Nutritional, Metabolic, Endocrine Diabetes

Interventions

The intervention is a 15-minute daily session of slow breathing exercise guided by the RESPeRATE device (http://www.resperate.com). The device monitors the user's breathing rate and pattern using a br

Sponsors

InterCure (Israel)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Non-insulin dependent diabetes mellitus 2. Average BP level, as measured in visits one and two: Systolic Blood Pressure (SBP) above 130 mmHg, and difference in BP levels between the two visits was not greater than 5 mmHg for SBP and 2 mmHg for Diastolic Blood Pressure (DBP) 3. Aged 40 to 79 years 4. No change in prescribed anti-hypertensive therapy, pharmacological or lifestyle modification for one month prior to visit one

Exclusion criteria

Exclusion criteria: 1. Taking insulin 2. Active ischaemic heart disease/unstable angina 3. Major stroke with major impairment 4. Pregnant woman 5. Obesity: body mass index greater than 40 6. Major psychiatric disorder 7. Unable to operate a portable tape 8. Blind or deaf 9. Participates in another study

Design outcomes

Primary

MeasureTime frame
Blood pressure: during each visit BP was measured.

Secondary

MeasureTime frame
Secondary outcomes are the validated QSD "Questionnaire of Stress in Diabetics", diastolic BP, fasting glucose, HbA1C and fructosamine. Questionnaire and blood tests for glucose, HbA1C and fructosamine were taken at baseline and end of follow-up.

Countries

Israel

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026